Zacks Research Issues Positive Outlook for Omnicell Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research upped their Q1 2025 earnings estimates for Omnicell in a research report issued to clients and investors on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company will earn $0.17 per share for the quarter, up from their previous forecast of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

A number of other equities analysts have also weighed in on the company. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Barclays raised their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Craig Hallum boosted their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $50.00.

Omnicell Stock Performance

OMCL stock opened at $45.31 on Thursday. The stock’s 50 day simple moving average is $44.68 and its 200 day simple moving average is $42.64. The company has a market cap of $2.10 billion, a P/E ratio of -116.18, a price-to-earnings-growth ratio of 29.73 and a beta of 0.78. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in the business. Van ECK Associates Corp increased its holdings in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the period. KBC Group NV increased its stake in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the last quarter. 1620 Investment Advisors Inc. raised its holdings in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the period. Finally, Summit Global Investments bought a new stake in shares of Omnicell in the 3rd quarter worth approximately $221,000. 97.70% of the stock is currently owned by institutional investors.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.64% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.